| Revision as of 21:23, 21 October 2006 edit207.224.163.105 (talk) link rot.← Previous edit | Revision as of 17:16, 6 November 2006 edit undoUrod (talk | contribs)Extended confirmed users1,691 edits →External linksNext edit → | ||
| Line 18: | Line 18: | ||
| * The June 2006 release of summarized Phase IIa test results for women, which indicated significantly increased sexual desire and arousal (67% and 72% respectively) in women diagnosed with ]. | * The June 2006 release of summarized Phase IIa test results for women, which indicated significantly increased sexual desire and arousal (67% and 72% respectively) in women diagnosed with ]. | ||
| * Norman Levine, MD; researcherss on Melanotan at University of Arizona Dermatology | * Norman Levine, MD; researcherss on Melanotan at University of Arizona Dermatology | ||
| * (]; cached HTML version is ) | |||
| ] | ] | ||
Revision as of 17:16, 6 November 2006
Bremelanotide (formerly PT-141) is the generic term for a new medication for use in treating sexual dysfunction in men (erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). It is a synthetic aphrodisiac. Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire. Bremelanotide is a spray introduced nasally.
Originally, the peptide Melanotan II that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in eight out of the ten original male volunteer test subjects. In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by Palatin Technologies.
Bremelanotide is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the melanocortin receptors MC3-R and MC4-R in the central nervous system. It has the amino acid sequence Ac-Nle-cyclo-OH or cyclo-alpha-MSH-(4-10). PT-141 is a metabolite of Melanotan II that lacks the C-terminal amide function. Its molecular forumla is C50H68N14O10 with a molecular weight of 1025.2.
In the United States it is currently in a Phase III clinical trial.
External links
- Palatin Technologies The company that has developed bremelanotide.
- US 6,794,489 bremelanotide (PT-141) patent (Appl. No.:040547)
- US 6,579,968 bremelanotide (PT-141) patent (Appl. No.:066501)
- Melanotan.org
- Proc. Nat. Acad. Sci 101: 10201 (2004) A scientific study with female rats.
- Review article (in German).
- The June 2006 release of The Bremelanotide Bulletin summarized Phase IIa test results for women, which indicated significantly increased sexual desire and arousal (67% and 72% respectively) in women diagnosed with female sexual arousal disorder.
- Norman Levine, MD; researcherss on Melanotan at University of Arizona Dermatology
- PT-141 fact sheet (PDF; cached HTML version is here)